The Modern Approaches to Prevention and Treatment of NSAID-Induced Gastropathy

S.M. Tkach

Abstract


The article presents recent data on the different tactics for treatment and prevention of NSAID-induced gastropathy. On the basis of the carried out analysis it has been concluded that the most effective strategies are the use of proton pomp inhibitors and eradication of  infection. The use of double doses of proton pomp inhibitors allows improving the efficacy of prevention and treatment of NSAID-induced gastropathy.

Keywords


non-steroidal anti-inflammatory drugs; NSAID-induced gastropathy; proton pomp inhibitors; Helicobacter pylori eradication

References


Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group / C. Bombardier, L. Laine, A. Reicin [et al.] // N. Engl. J. Med. — 2000. — Vol. 343. — P. 1520-1528.

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modeling / T.J. Brown, L. Hooper, R.A. Elliott [et al.] // Health Technol. Assess. — 2006. — Vol. 10. — P. 1-183.

Chan F.K. NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management / F.K. Chan // Drug Saf. — 2005. — Vol. 28. — P. 287-300.

Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial / F.K. Chan, L.C. Hung, B.Y. Suen [et al.] // Gastroenterology. — 2004. — Vol. 127. — P. 1038-1043.

Combination of a cyclooxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial / F.K. Chan, V.W. Wong, B.Y. Suen [et al.] // Lancet. — 2007. — Vol. 369. — P. 1621-1626.

CONDOR: Celecoxib vs. Omeprazole and Diclofenac for at-risk Osteoarthritis and Rheumatoid arthritis patients Clinical Trials. Gov. Identifier: NCT00141102; http://clinicaltri-als.gov/show/NCT00141102 Accessed January 7, 2008.

Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users / D. Cullen, K.D. Bardhan, M. Eisner [et al.] // Aliment. Pharmacol. Ther. — 1998. — Vol. 12. — P. 135-140.

Current concepts in the management of Helicobacter pylori infection. The Maastricht 2 –2000 Consensus Report, September, Rome, 2000.

Derry S. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis / S. Derry, Y.K. Loke // BMJ. — 2000. — Vol. 321. — P. 1183-1187.

Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multicentre study / P. Ekstrom, L. Carling, S. Wetterhus [et al.] // Scand. J. Gastroenterol. — 1996. — Vol. 31. — P. 753-758.

Fries J. NSAID-associated gastropathy: incidence and risk factor model / J. Fries, C. Williams, D. Bloch // Am. J. Med. — 1991. — Vol. 91. — P. 213-222.

Identification of patients at risk for gastropathy associated with NSAID use / J.F. Fries, S.R. Miller, P.W. Spitz [et al.] // J. Rheumatol. — 1990. — Vol. 20. — P. 12-19.

Gabriel S.E. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis / S.E. Gabriel, L. Jaakkimainen, C. Bombardier // Ann. Intern. Med. — 1991. — Vol. 115. — P. 787-796.

Garcia Rodriguez L.A. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs / L.A. Garcia Rodriguez, H. Jick // Lancet. — 1994. — Vol. 343. — P. 769-772.

Goldstein J.L., Fort J.G. Incidence of endoscopic gastroduodenal ulcers in subjects on 325 mg qd of aspirin for cardiovascular prophylaxis with placebo, a COX-2 specific inhibitor, or a nonspecific NSAID: Results from a randomized, double-blind, controlled trial GA, American College of Rheumatology Annual Meeting [Poster LB14/523]. — 23–28 October, 2003, Orlando, FL.

Griffin M.R., Piper J.M., Daugherty J.R. et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons // Ann. Intern. Med. — 1991. — Vol. 114. — P. 257-263.

Hawkey C., Talley N.J., Yeomans N.D. et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors // Am. J. Gastroenterol. — 2005. — Vol. 100. — P. 1028-1036.

Hawkey C.J. Nonsteroidal anti-inflammatory drug gastropathy // Gastroenterology. — 2000. — Vol. 119. — P. 521-535.

Hawkey C.J., Karrasch J.A., Szczepanski L. et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced Ulcer Management, OMNIUM Study Group // N. Engl. J. Med. — 1998. — Vol. 338. — P. 727-734.

Hawkey C.J., Karrasch J.A., Szczpanski L. et al. Omeprazole compared with misoprostol for ulcers associated with NSAID // N. Engl. J. Med. — 1998. — Vol. 338. — P. 727-734.

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis / D. Henry, L.L. Lim, Garcia L.A. Rodriguez [et al.] // BMJ. — 1996. — Vol. 312. — P. 1563-1566.

Hernandez-Diaz S., Rodriguez L.A. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s / S. Hernandez-Diaz, L.A. Rodriguez // Arch. Intern. Med. — 2000. — Vol. 160. — P. 2093-2099.

Jensen D., Ho S., Hamamah S. et al. A randomized study of omeprazole compared to misoprostol for prevention of recurrent ulcers and ulcer hemorrhage in high risk patients ingesting aspirin or NSAIDS // Gastroenterology. — 2000. — Vol. 118. — P. A892.

A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole / J. Labenz, K.U. Petersen, W. Rosch [et al.] // Aliment. Pharmacol. Ther. — 2003. — Vol. 17. — P. 1015-1019.

Laine L. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis / L. Laine, C. Bombardier, C.J. Hawkey // Gastroenterology. — 2002. — Vol. 123. — P. 1006-1012.

Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs / L.M. Jangman, J. Weil, P. Wainwright [et al.] // Lancet. — 1994. — Vol. 343. — P. 1075-1078.

Lee M., Feldman M. The aging stomach: implications for NSAID gastropathy / M. Lee, M. Feldman // Gut. — 1997. — Vol. 41. — P. 425-426.

Current concepts in the management of Helicobacter pylori infection — The Maastricht III Consensus Report / P. Malfertheiner, F. Megraud, C. O’Moran [et al.] // Gut. — 2007. — Vol. 56. — P. 772-781.

McNamara D. Gastrooesophageal reflux disease and ulcer disease in Europe. — P. NSAID-related gastroduodenal pathology / D. McNamara // The Burden of Gastrointestinal Diseases in Europe. — 2004. — P. 31-36.

Review article: NSAIDs, gastroprotection and cyclo-xygenase-II-selective inhibitors / R. Micklewrigh, S. Lane, W. Linley [et al.] // Aliment. Pharmacol. Ther. — 2003. — Vol. 17. — P. 321-332.

Endoscopy in asymptomatic minidose aspirin consumers / Y. Niv, A. Battler, G. Abuksis [et al.] // Dig. Dis. Sci. — 2005. — Vol. 50. — P. 78-80.

Piper J. Corticosteroid use and peptic ulcer disease: role of NSAID / J. Piper, W. Ray, J. Daugherthy // Ann. Intern. Med. — 1991. — Vol. 114. — P. 735-740.

Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment: a double blind placebo controlled study / B.G. Porro, M. Lazzaroni, M. Petrillo [et al.] // Ital. J. Gastroenterol. Hepatol. — 1998. — Vol. 30. — P. 43-47.

Prevention of NSAID-induced gastroduodenal ulcers / A. Rostom, C. Dube, G. Wells [et al.] // Cochrane Database Syst. Rev. — 2002. — CD002296.

Saini S.D., Schoenfeld P., Fendrick A.M. et al. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention // Arch. Intern. Med. — 2008. — Vol. 168. — P. 1684-1690.

Shorr R. Concurrent use of NSAID and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease / R. Shorr, W. Ray, J. Daugherrty // Arch. Inter. Med. — 1993. — Vol. 153. — P. 1665-1670.

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial / F.E. Silverstein, D.Y. Graham, J.R. Senior [et al.] // Ann. Intern. Med. — 1995. — Vol. 123. — P. 241-249.

Slattery J. Risk of gastroinestinal bleeding during secondary prevention of vascular events with aspirin: UK-TIA Trial / J. Slattery, C. Warlow, C. Shoeeock // Gut. — 1995. — Vol. 37. — P. 509-511.

Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs / W.E. Smalley, M.R. Griffin, R.L. Fought [et al.] // J. Gen. Intern. Med. — 1996. — Vol. 11. — P. 461-469.

Spiegel B.M. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups / B.M. Spiegel, C.F. Chiou, J.J. Ofman // Arthritis Rheum. — 2005. — Vol. 53. — P. 185-197.

Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis / B.M. Spiegel, M. Farid, G.S. Dulai [et al.] //Am. J. Med. — 2006. — Vol. 119. — P. 427-436.

Stalnikowicz R., Rachmilewitz D. NSAID-induced gastroduo-denal damage: is prevention needed? A review and meta-analysis // J. Clin. Gastroenterol. — 1993. — Vol. 17. — P. 238-243.

Van Leen M.W. Prevention of NSAID gastropathy in elderly patients: an observational study in general practice and nursing homes / van M.W. Leen, van der I. Eijk, J.M. Schols // Age Ageing. — 2007. — Vol. 36. — P. 414-418.

Weil J. Prophylactic aspirin and risk of peptic ulcer bleeding / J. Weil, D. Colin-Jones, N. Langman // Br. Med J. — 1995. — Vol. 310. — P. 827-830.

Wilcox C.M. Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage / C.M. Wilcox, K.A. Shalek, G. Cotsonis // Arch. Intern. Med. — 1994. — Vol. 154. — P. 42-46.

Wolfe M.M. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs / M.M. Wolfe, D.R. Lichtenstein, G. Singh // N. Engl. J. Med. — 1999. — Vol. 340. — P. 1888-1899.

A comparison of omeprazole with ranitidine for ulcers associated with nons-teroidal antiinflammatory drugs, Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment, ASTRONAUT Study Group / N.D. Yeomans, Z. Tulassay, L. Juhasz [et al.] // N. Engl. J. Med. — 1998. — Vol. 338. — P. 719-726.




DOI: https://doi.org/10.22141/2308-2097.4.50.2013.86397

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru